110 related articles for article (PubMed ID: 9215609)
1. Effect of low-dose 1-hydroxyvitamin D3 in a patient with myelodysplasia after induction therapy for acute myelocytic leukemia.
Fujisawa S; Motomura S; Sakai R; Tomita N; Fujimaki K; Mohri H; Okubo T
Anticancer Drugs; 1997 Jun; 8(5):466-7. PubMed ID: 9215609
[No Abstract] [Full Text] [Related]
2. Hematologic benefits of 1-hydroxyvitamin D3 in an elderly patient with chronic myelodysplastic syndrome.
Motomura S; Fujisawa S; Tsunooka S; Fujimaki K; Mohri H; Okubo T
Am J Hematol; 1996 Oct; 53(2):143-4. PubMed ID: 8892744
[No Abstract] [Full Text] [Related]
3. [Treatment of myelodysplastic syndrome and acute myelogenous leukemia with vitamin D3 (1 alpha(OH)D3)].
Taoka T; Hamamoto T; Okuda Y; Hata Y; Kubota Y; Tanaka T; Irino S; Miyazaki T; Ohbayashi S
Rinsho Ketsueki; 1987 Jun; 28(6):830-8. PubMed ID: 3478504
[No Abstract] [Full Text] [Related]
4. Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG).
Hellström E; Robèrt KH; Samuelsson J; Lindemalm C; Grimfors G; Kimby E; Oberg G; Winqvist I; Billström R; Carneskog J
Eur J Haematol; 1990 Nov; 45(5):255-61. PubMed ID: 2261951
[TBL] [Abstract][Full Text] [Related]
5. The effect of 1-hydroxyvitamin D3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes.
Motomura S; Kanamori H; Maruta A; Kodama F; Ohkubo T
Am J Hematol; 1991 Sep; 38(1):67-8. PubMed ID: 1897516
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow and serum concentrations of 25-hydroxyvitamin D, 24,25-dihydroxyvitamin D, and 1 alpha,25-dihydroxyvitamin D in patients with leukemia and normal subjects.
Masuda S; Okano T; Noma K; Hamasaki M; Kobayashi T; Oh H; Yoshida S
J Nutr Sci Vitaminol (Tokyo); 1989 Aug; 35(4):211-23. PubMed ID: 2585143
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic trial of hematological disorders with intermittent administration of high-dose 1-alpha-hydroxyvitamin D3.
Imai Y; Tsutsumi M; Tsunenari T; Nishikawa M; Matsui T; Natazuka T; Fujita T
Contrib Nephrol; 1991; 91():95-101. PubMed ID: 1800016
[TBL] [Abstract][Full Text] [Related]
8. Myelodysplastic relapse of de novo acute myeloid leukaemia with trilineage myelodysplasia.
Ng JP; Pati A; Strevens MJ; Swart S
Br J Haematol; 1988 Aug; 69(4):578. PubMed ID: 3165675
[No Abstract] [Full Text] [Related]
9. Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute myelogenous leukemia.
Maiolo AT; Foa P; Cortellaro M; Lambertenghi-Deliliers G; Colantoni A; Cesana B; Castoldi GL; Cazzola M; Giordano M; Riccardi A
Haematologica; 1987; 72(1):61-5. PubMed ID: 3108098
[No Abstract] [Full Text] [Related]
10. Results of combination therapy with amifostine, pentoxifylline, ciprofloxacin and dexamethasone in patients with myelodysplastic syndrome and acute myeloid leukemia.
Erikci AA; Ozturk A; Karagoz B; Bilgi O; Turken O; Top C; Kandemir EG
Hematology; 2008 Oct; 13(5):289-92. PubMed ID: 18854092
[TBL] [Abstract][Full Text] [Related]
11. Therapy-related myelodysplasia and fludarabine combination therapy - do the benefits justify the risk?
Carney DA; Seymour JF
Leuk Lymphoma; 2010 Nov; 51(11):1957-9. PubMed ID: 20858101
[No Abstract] [Full Text] [Related]
12. Low serum vitamin D levels are associated with shorter survival after first-line azacitidine treatment in patients with myelodysplastic syndrome and secondary oligoblastic acute myeloid leukemia.
Radujkovic A; Schnitzler P; Ho AD; Dreger P; Luft T
Clin Nutr; 2017 Apr; 36(2):542-551. PubMed ID: 26899917
[TBL] [Abstract][Full Text] [Related]
13. Case report of isochromosome 17q in acute myeloid leukemia with myelodysplasia-related changes after treatment with a hypomethylating agent.
Sousa JC; Germano RT; Castro CC; Magalhaes SM; Pinheiro RF
Genet Mol Res; 2012 Aug; 11(3):2045-50. PubMed ID: 22911588
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of a patient with acute myeloid leukemia with 1 alpha(OH)D3.
Nakayama S; Ishikawa T; Yabe H; Nagai K; Kasakura S; Uchino H
Nihon Ketsueki Gakkai Zasshi; 1988 Sep; 51(6):1026-30. PubMed ID: 3201896
[No Abstract] [Full Text] [Related]
15. Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype.
Scherman E; Malak S; Perot C; Gorin NC; Rubio MT; Isnard F
Leukemia; 2012 Apr; 26(4):822-4. PubMed ID: 21997572
[No Abstract] [Full Text] [Related]
16. Therapy-related myelodysplasia and acute myeloid leukemia following paclitaxel- and carboplatin-based chemotherapy in an ovarian cancer patient: a case report and literature review.
Yeasmin S; Nakayama K; Ishibashi M; Oride A; Katagiri A; Purwana IN; Iida K; Nakayama N; Ishikura H; Miyazaki K
Int J Gynecol Cancer; 2008; 18(6):1371-6. PubMed ID: 18217963
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
[TBL] [Abstract][Full Text] [Related]
18. Trilineage response to recombinant human granulocyte colony-stimulating factor administration in a patient with myelodysplastic syndrome.
Rey C; Bader-Meunier B; Tertian G; Mielot F; Tchernia G; Yver A
Am J Hematol; 1993 May; 43(1):76-7. PubMed ID: 7686335
[No Abstract] [Full Text] [Related]
19. [Role of vitamin D3 in hematology].
Petrini M; Bilancia D; Risaliti M; Ambrogi F; Grassi B
Clin Ter; 1989 Jan; 128(1):33-8. PubMed ID: 2525990
[TBL] [Abstract][Full Text] [Related]
20. Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature.
Noronha V; Berliner N; Ballen KK; Lacy J; Kracher J; Baehring J; Henson JW
Neuro Oncol; 2006 Jul; 8(3):280-3. PubMed ID: 16728498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
